Hyperpigmented rash of imatinib
Imatinib is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Inhibition of c-kit causes melanocyte dysfunction, thereby leading to dermatological side effects. It causes various skin side effects and hypopigmented rash being common. We report a rare case of a hyperpigmented rash of Imatinib.
Authors
- Pankaj Tyagi (ORCID: https://orcid.org/0000-0002-7003-0489)
- Karan Sood (ORCID: https://orcid.org/0000-0003-1510-2053)
Institutions
- Jawaharlal Nehru Medical College Hospital (IN)
- Jawaharlal Nehru Medical College (IN)
- Jawaharlal Nehru Medical College (IN)
Publication Details
- Journal
- International Journal of Molecular and Immuno Oncology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.25259/ijmio_5_2025
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00